USFDA6 Sept 2025, 09:31 am
Lupin Ltd Receives Two Observations from U.S. FDA in Pre-Approval Inspection
AI Summary
Lupin Ltd, a prominent pharmaceutical company, has recently undergone a product-specific Pre-Approval Inspection (PAI) by the U.S. FDA at its Chhatrapati Sambhajinagar (Aurangabad) manufacturing facility. The inspection, which took place from September 01 to September 05, 2025, resulted in two observations. The company has committed to addressing these observations and responding to the U.S. FDA within the specified timeframe. Lupin Ltd is dedicated to maintaining compliance with CGMP quality standards across all its facilities.
Key Highlights
- Lupin Ltd underwent a product-specific Pre-Approval Inspection by the U.S. FDA at its Aurangabad facility
- The inspection took place from September 01 to September 05, 2025
- Two observations were issued by the U.S. FDA
- Lupin Ltd is committed to addressing these observations and responding within the stipulated timeframe
- The company is dedicated to maintaining compliance with CGMP quality standards across all its facilities